Multimorbidity
Exam Tips
- In UK exams, define multimorbidity as >=2 long-term conditions and include mental health/chronic infection/frailty domains, not only physical disease.
- Quote high-yield epidemiology: prevalence rises strongly with age, but many affected people are <65 and deprivation shifts onset 10-15 years earlier.
- Risk-stratify medication harm: 10-14 regular medicines suggests elevated risk; >=15 strongly predicts adverse events/interactions.
- Use a structured OSCE approach: disease burden, treatment burden, patient goals, mental health screen, social context, and carer involvement.
- Frailty pearls: avoid physical performance frailty testing during acute illness; in stable patients, >5 seconds for 4-m walk suggests frailty.
- Management marks come from prioritisation and deprescribing safety (withdrawal planning, interaction checks, and shared decisions), not adding more drugs.
Definition
Multimorbidity is the coexistence of two or more long-term health conditions in one person, spanning physical illness, mental illness, chronic infection, and syndromic problems such as frailty or chronic pain. In UK practice it is best understood as a whole-person state in which interacting diseases and treatments create cumulative burden, rather than a simple count of diagnoses.
Pathophysiology
Multimorbidity develops through overlap of shared risk pathways (ageing, deprivation, inactivity, obesity, tobacco/alcohol exposure), biological processes (chronic low-grade inflammation, vascular/end-organ damage, reduced physiological reserve), and psychosocial stressors that impair self-management. Conditions then amplify each other (for example, diabetes plus vascular disease plus depression), while treatment complexity drives polypharmacy, adverse drug reactions, and prescribing cascades. The net effect is reduced resilience, higher frailty risk, and greater vulnerability to decompensation from minor illness or medication changes.
Risk Factors
- Increasing age (prevalence rises markedly in older groups)
- Female sex
- Socioeconomic deprivation (earlier onset, including physical-mental comorbidity)
- Pre-existing chronic conditions (for example hypertension, osteoporosis, diabetes)
- Smoking and harmful alcohol use
- Physical inactivity
- Poor diet and obesity
- Pregnancy (higher chance of concurrent conditions)
Clinical Features
Symptoms
- High treatment burden: difficulty keeping up with appointments, medicines, and lifestyle plans
- Reduced quality of life, fatigue, pain, and reduced participation in work/family/social roles
- Psychological symptoms such as low mood, anxiety, or overwhelm
- Functional decline: reduced mobility, falls risk, loss of independence
- Frequent unplanned-care presentations
Signs
- Polypharmacy on medication reconciliation (especially 10+ regular medicines; very high risk at 15+)
- Frailty markers (slow gait speed, low self-rated health, dependence in activities)
- Evidence of multimodal service use (multiple specialties/providers involved)
- Cognitive or sensory impairment affecting adherence and self-care
- Adverse drug effect patterns (postural hypotension, confusion, constipation, AKI, falls)
Investigations
Management
Lifestyle Modifications
- Use shared decision-making to set patient-prioritised goals (function, symptom control, independence, prevention priorities)
- Reduce treatment burden by simplifying appointments, aligning reviews, and coordinating across services
- Promote physical activity, nutrition optimisation, smoking cessation, and alcohol reduction tailored to capacity
- Strengthen self-management support, health literacy, and carer involvement (with consent)
- Falls prevention and functional interventions (strength/balance work, home hazard review) when frailty risk is present
Pharmacological Treatment
Polypharmacy optimisation / deprescribing
- No single drug treats multimorbidity; perform indication-by-indication review and stop non-beneficial medicines
Prioritise medicines with current benefit aligned to patient goals; taper withdrawal-risk drugs (for example benzodiazepines, opioids, beta-blockers) rather than abrupt cessation; check interactions and cumulative anticholinergic/sedative burden.
Analgesia rationalisation (if chronic pain contributes)
- Paracetamol 1 g up to four times daily (maximum 4 g/day in adults)
Use lowest effective dose and review benefit; reduce maximum dose in low body weight, frailty, or liver impairment; avoid routine long-term NSAIDs in high GI/renal/CV-risk patients without protection and monitoring.
Cardiovascular risk treatment when indicated by comorbidity profile
- Atorvastatin 20 mg once nightly for primary prevention where indicated
- Atorvastatin 80 mg once nightly for secondary prevention where tolerated
Individualise to frailty, life expectancy, and patient priorities; monitor for myalgia/hepatotoxicity and interactions; avoid in active liver disease and use caution in severe frailty where time-to-benefit may exceed likely gain.
Glycaemic treatment simplification in type 2 diabetes (if present)
- Metformin immediate-release 500 mg once daily with food, titrated gradually
Choose regimens that minimise hypoglycaemia and burden; review renal function and avoid/adjust in significant renal impairment; suspend during acute dehydrating illness to reduce lactic acidosis risk.
Complications
- Reduced quality of life and functional decline
- Reduced life expectancy
- High treatment burden with poor adherence
- Depression/anxiety and worsening mental wellbeing
- Care fragmentation and coordination failures
- Polypharmacy-related adverse drug events and drug-drug interactions
- Increased emergency and unplanned healthcare use
- Carer strain and reduced carer wellbeing
Prognosis
Prognosis is heterogeneous and depends on condition mix, frailty, deprivation, mental health comorbidity, and medication burden. Earlier recognition with person-centred prioritisation and active deprescribing can improve function, safety, and quality of life, even when cure is not possible.
Sources & References
✅NICE Guidelines(1)
- Multimorbidity[overview]